Industry

DUBLIN–(BUSINESS WIRE)–The “North America Antibody Drug Conjugates Market – Forecasts from 2022 to 2027” report has been added to ResearchAndMarkets.com’s offering. Market Drivers The rising prevalence of cancer is the primary driver of the antibody drug conjugates market in North America. Because cancer claims millions of lives each year and is on the rise, the … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Cathepsin K Inhibitor – Pipeline Insight, 2022” clinical trials has been added to ResearchAndMarkets.com’s offering. “Cathepsin K Inhibitor – Pipeline Insight, 2022” report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Cathepsin K Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Isocitrate Dehydrogenase (IDH) inhibitors- Pipeline Insight, 2022” clinical trials has been added to ResearchAndMarkets.com’s offering. This “Isocitrate Dehydrogenase (IDH) inhibitors – Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Isocitrate Dehydrogenase (IDH) inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Corporate Wellness Market Intelligence Report – Global Forecast to 2027” report has been added to ResearchAndMarkets.com’s offering. The Global Corporate Wellness Market is projected to reach USD 81,715.37 million by 2027 from USD 42,138.66 million in 2021, at a CAGR 11.67% during the forecast period. Market Statistics: The Americas Corporate Wellness Market size … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Progesterone Receptor (PR) Antagonist – Pipeline Insight, 2022” clinical trials has been added to ResearchAndMarkets.com’s offering. “Progesterone Receptor (PR) Antagonist – Pipeline Insight, 2022” offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Progesterone Receptor (PR) Antagonist development. The report provides detailed coverage of the pipeline landscape for … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Comprehensive Metabolic Panel (CMP) Testing Market Analysis by Disease Type (Diabetes, Kidney Disease, Liver Disease), by End User (Point Of Contact (PoC), Laboratories), and by Region – Forecast to 2029” report has been added to ResearchAndMarkets.com’s offering. The global comprehensive metabolic panel (CMP) testing market size is estimated to be USD 12.5 billion … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Interventional Neurology Market Analysis by Product (Cerebral Balloon Angioplasty and Stenting Systems, Aneurysm Coiling & Embolization Devices), by Disease (Arteriovenous Malformation and Fistulas, Cerebral Aneurysms, Ischemic Strokes), and by Region – Forecast to 2029” report has been added to ResearchAndMarkets.com’s offering. The global interventional neurology market size is estimated to be USD 2,702.4 … [Read more…]

Agenda Includes Improving the Participant Experience, Post-Pandemic Employee Benefit Perceptions, and Diversity, Equity, and Inclusion Initiatives WASHINGTON–(BUSINESS WIRE)–ECFC, the leading nonprofit organization promoting choice in consumer-driven benefit solutions, will hold its 35th Annual Symposium on August 3-5 to educate benefits industry professionals on evolving healthcare trends in a post-pandemic healthcare environment. The 35th Annual Symposium … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Brain Cancer Treatment Drugs Markets in China” report has been added to ResearchAndMarkets.com’s offering. China’s demand for Brain Cancer Treatment Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has … [Read more…]

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that ALBRIOZA™ (sodium phenylbutyrate and ursodoxicoltaurine) is now commercially available in Canada for people living with amyotrophic lateral sclerosis (ALS). ALBRIOZA (also known as AMX0035) is an oral fixed-dose combination therapy that may reduce neuronal cell death as a stand-alone therapy or … [Read more…]